药物治疗胆汁淤积性肝病的研究进展
Research Progress on Pharmacological Treatment for Cholestatic Liver Disease
DOI: 10.12677/jcpm.2024.34320, PDF,    科研立项经费支持
作者: 金浩源, 王德强*, 李浩天, 贾辰昊, 周秉昌：内蒙古科技大学包头医学院第一附属医院肝胆胰脾外科，内蒙古 包头
关键词: 胆汁淤积性肝病；药物治疗；中医治疗；Cholestatic Liver Disease； Pharmacological Treatment； Traditional Chinese Medicine Therapy
摘要: 胆汁淤积性肝病是指由各种原因导致胆汁形成、分泌、排泄异常，从而引起肝脏发生病变。目前，胆汁淤积性肝病治疗主要通过熊去氧胆酸及法尼醇X受体激动剂奥贝胆酸。近些年发现成纤维细胞生长因子-19和过氧化物酶体增殖物激活受体激动剂也在治疗中发挥作用。此外，国内外多项实验研究证实顶端钠依赖性胆酸转运体抑制剂、免疫治疗和中医治疗也是治疗胆汁淤积性肝病的潜在方法。本文旨在对胆汁淤积性肝病及其治疗药物的研究进展进行阐述，为治疗此类疾病的方向提供更多的参考依据。
Abstract: Cholestatic liver disease is a condition in which bile formation, secretion, and excretion are abnormal for various reasons, resulting in liver lesions. Currently, cholestatic liver disease is treated mainly by ursodeoxycholic acid and the farnesol X receptor agonist obeticholic acid. In recent years, fibroblast growth factor-19 and peroxisome proliferator-activated receptor agonists have also been found to play a role in the treatment. In addition, several experimental studies at home and abroad have confirmed that apical sodium-dependent bile acid transporter inhibitors, immunotherapy, and traditional Chinese medicine therapy are also potential treatments for cholestatic liver disease. The purpose of this paper is to describe the research progress of cholestatic liver disease and its therapeutic drugs and to provide more references for the direction of the treatment of such diseases.
文章引用：金浩源, 王德强, 李浩天, 贾辰昊, 周秉昌. 药物治疗胆汁淤积性肝病的研究进展[J]. 临床个性化医学, 2024, 3(4): 2248-2255. https://doi.org/10.12677/jcpm.2024.34320

参考文献

[1] 杨玲, 范慧倩, 严胜琦. 胆汁淤积性肝病治疗进展[J]. 内科理论与实践, 2022, 17(1): 29-37.
[2] 于乐成, 陈成伟. 胆汁淤积性肝病的诊治现状及研究方向[J]. 临床肝胆病杂志, 2019, 35(2): 241-246.
[3] 陆伦根, 蔡晓波, 王建设, 等. 胆汁淤积性肝病管理指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 62-69.
[4] 张文胜, 王宝恩, 贾继东. 特发性成人肝内胆管缺失症[J]. 肝脏, 2004, 9(4): 264-266.
[5] Douglass, K.M., Willner, I.R., Glenn, D.J. and Jones, R.M. (2020) Idiopathic Adulthood Ductopenia Causing Cirrhosis. ACG Case Reports Journal, 7, e00349. [Google Scholar] [CrossRef] [PubMed]
[6] 尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 35-41.
[7] Luo, X. and Lu, L. (2024) Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going? Journal of Clinical and Translational Hepatology, 12, 581-588. [Google Scholar] [CrossRef] [PubMed]
[8] 罗攀月, 赵志斌, 廉哲雄. 原发性胆汁性胆管炎的发病机制及临床诊疗[J]. 中西医结合肝病杂志, 2021, 31(4): 303-307.
[9] Dias, T., Ferreira, D., Moreira, H., Nascimento, T., Santos, A. and Carvalho, A. (2019) A Case of Severe Cholestasis Due to Hepatic AL Amyloidosis. GE—Portuguese Journal of Gastroenterology, 26, 425-429. [Google Scholar] [CrossRef] [PubMed]
[10] Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S.O., Palladini, G., Hawkins, P.N., et al. (2018) Systemic Immunoglobulin Light Chain Amyloidosis. Nature Reviews Disease Primers, 4, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, J. and Ling, X. (2020) Risk Factors and Management of Primary Choledocholithiasis: A Systematic Review. ANZ Journal of Surgery, 91, 530-536. [Google Scholar] [CrossRef] [PubMed]
[12] 吴迪, 卢忠义, 唐钟灵, 等. 血清GGT与ALP联合检测对无症状继发性胆总管结石诊断价值的临床研究[J]. 现代预防医学, 2020, 47(11): 2099-2102.
[13] Mohamed, M.F.H., Elfert, K., Wadhavkar, N., Marino, D., Farrakhan, K., Beran, A., et al. (2023) Choledocholithiasis Can Present with Marked Transaminases Elevation: Systematic Review and Meta-analysis. Digestive Diseases and Sciences, 68, 3428-3435. [Google Scholar] [CrossRef] [PubMed]
[14] 王涛, 吴清明, 龙辉. 原发性硬化性胆管炎的诊治进展[J]. 现代医学, 2021, 49(3): 363-368.
[15] 于建安, 贾翠宇, 武志岗, 等. 原发性硬化性胆管炎的临床和影像学特征分析[J]. 北京医学, 2022, 44(10): 897-901+906.
[16] 李琳, 李杨, 林楠, 等. 原发性硬化性胆管炎25例临床分析[J]. 中国临床研究, 2020, 33(7): 922-926.
[17] 郭长存, 时永全, 尚玉龙, 等. 原发性硬化性胆管炎诊断及治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(1): 50-61.
[18] Tow, C.Y., Chung, E., Kaul, B., Bhalla, A. and Fortune, B.E. (2024) Diagnostic Tests in Primary Sclerosing Cholangitis: Serology, Elastography, Imaging, and Histology. Clinics in Liver Disease, 28, 157-169. [Google Scholar] [CrossRef] [PubMed]
[19] 陈瑞玲, 马雄. 胆汁淤积导致肝纤维化的机制及其阻断策略[J]. 临床肝胆病杂志, 2019, 35(2): 247-251.
[20] Paumgartner, G. and Beuers, U. (2002) Ursodeoxycholic Acid in Cholestatic Liver Disease: Mechanisms of Action and Therapeutic Use Revisited. Hepatology, 36, 525-531. [Google Scholar] [CrossRef] [PubMed]
[21] Zhang, Y., Jiang, R., Zheng, X., Lei, S., Huang, F., Xie, G., et al. (2019) Ursodeoxycholic Acid Accelerates Bile Acid Enterohepatic Circulation. British Journal of Pharmacology, 176, 2848-2863. [Google Scholar] [CrossRef] [PubMed]
[22] Younossi, Z.M., Bernstein, D., Shiffman, M.L., Kwo, P., Kim, W.R., Kowdley, K.V., et al. (2019) Diagnosis and Management of Primary Biliary Cholangitis. American Journal of Gastroenterology, 114, 48-63. [Google Scholar] [CrossRef] [PubMed]
[23] Ozkol, H.U., Calka, O., Dulger, A.C. and Bulut, G. (2013) Ursodeoxycholic Acid Induced Generalized Fixed Drug Eruption. Cutaneous and Ocular Toxicology, 33, 256-258. [Google Scholar] [CrossRef] [PubMed]
[24] 贾皖婷, 刘晓晓, 邰文琳. 胆汁酸代谢在原发性胆汁性胆管炎发病机制中的作用[J]. 临床肝胆病杂志, 2022, 38(10): 2362-2367.
[25] 周珈旭. 胆汁酸受体法尼酯衍生物X受体拮抗剂的设计与合成[D]: [硕士学位论文]. 上海: 中国科学院大学, 2022.
[26] 邢苗苗, 张晓燕, 管又飞. 奥贝胆酸的研究进展[J]. 基础医学与临床, 2019, 39(10): 1494-1498.
[27] Sala, F., Mulet, J., Choi, S., Jung, S., Nah, S., Rhim, H., et al. (2002) Effects of Ginsenoside Rg2 on Human Neuronal Nicotinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics, 301, 1052-1059. [Google Scholar] [CrossRef] [PubMed]
[28] Molinaro, A. and Marschall, H. (2022) Bile Acid Metabolism and FXR-Mediated Effects in Human Cholestatic Liver Disorders. Biochemical Society Transactions, 50, 361-373. [Google Scholar] [CrossRef] [PubMed]
[29] Nevens, F., Trauner, M. and Manns, M.P. (2023) Primary Biliary Cholangitis as a Roadmap for the Development of Novel Treatments for Cholestatic Liver Diseases. Journal of Hepatology, 78, 430-441. [Google Scholar] [CrossRef] [PubMed]
[30] Rinella, M.E., Lieu, H.D., Kowdley, K.V., Goodman, Z.D., Alkhouri, N., Lawitz, E., et al. (2023) A Randomized, Double-Blind, Placebo-Controlled Trial of Aldafermin in Patients with NASH and Compensated Cirrhosis. Hepatology, 79, 674-689. [Google Scholar] [CrossRef] [PubMed]
[31] 吕艳, 杨益大. 原发性胆汁性胆管炎药物治疗新进展[J]. 实用肝脏病杂志, 2021, 24(6): 772-775.
[32] Wagner, M. and Fickert, P. (2020) Drug Therapies for Chronic Cholestatic Liver Diseases. Annual Review of Pharmacology and Toxicology, 60, 503-527. [Google Scholar] [CrossRef] [PubMed]
[33] 唐丽. 熊去氧胆酸 + 苯扎贝特治疗原发性胆汁性胆管炎的临床效果[J]. 临床医学研究与实践, 2019, 4(6): 29-31.
[34] 姜晗. 苯扎贝特联合熊去氧胆酸治疗原发性胆汁性肝硬化患者的临床效果[J]. 中国药物经济学, 2019, 14(8): 113-115, 119.
[35] 马昱杭, 韩昀屹, 韩者艺. 顶端钠依赖性胆酸转运体及其在相关疾病中的作用研究进展[J]. 陕西医学杂志, 2022, 51(9): 1163-1166.
[36] 张国强, 文苑洁, 董毓松, 等. 基于回肠顶端钠依赖性胆酸转运体探究栀子水提物对小鼠胆汁淤积的治疗作用[J]. 中草药, 2023, 54(1): 122-130.
[37] Li, M., Wang, Q., Li, Y., Cao, S., Zhang, Y., Wang, Z., et al. (2020) Apical Sodium-Dependent Bile Acid Transporter, Drug Target for Bile Acid Related Diseases and Delivery Target for Prodrugs: Current and Future Challenges. Pharmacology & Therapeutics, 212, Article ID: 107539. [Google Scholar] [CrossRef] [PubMed]
[38] Савельева, Е.Е., Тютрина, Е.С., Наканиши, Т., et al. (2020) Ингибиторы натрий-зависимого переносчика желчных кислот (ASBT) как перспективные лекарственные средства. Биомедицинская химия, 66, 185-195.
[39] Gossard, A.A. and Lindor, K.D. (2019) Current and Promising Therapy for Primary Biliary Cholangitis. Expert Opinion on Pharmacotherapy, 20, 1161-1167. [Google Scholar] [CrossRef] [PubMed]
[40] Wang, Z., Jin, R., Hao, M., Xie, Y., Liu, Z., Wang, X., et al. (2022) Treatment of Ursodeoxycholic Acid with Glucocorticoids and Immunosuppressants May Improve the Long-Term Survival Rate in Primary Biliary Cholangitis Patients. Medicine, 101, e31395. [Google Scholar] [CrossRef] [PubMed]
[41] Cataletti, G., Santagata, F., Pastorelli, L. and Battezzati, P.M. (2024) Severe Azathioprine-Induced Liver Injury 22 Months after Initiation of Treatment. Drug and Therapeutics Bulletin, 62, 60-63. [Google Scholar] [CrossRef] [PubMed]
[42] 王开霞, 郑超, 朱晓骏, 等. 茵陈五苓散治疗胆汁淤积研究进展[J]. 陕西中医, 2019, 40(12): 1822-1824.
[43] 李文楷. 黄芪汤抗DDC诱导的小鼠慢性胆汁淤积性肝损伤作用及机制研究[D]: [博士学位论文]. 上海: 上海中医药大学, 2019.
[44] 陈俊, 辛宝, 解方园, 等. 基于网络药理学探讨苦黄注射液保肝退黄作用机制[J]. 第二军医大学学报, 2019, 40(10): 1117-1123.
[45] 曹晓春, 王芳, 潘贤明. 茵泽温肝方治疗寒湿困脾型胆汁淤积性性肝病疗效及对患者肝功能的影响[J]. 西部中医药, 2023, 36(9): 106-109.
[46] 郭海军, 佟雪飞, 狄伟伟. 茵泽温肝方联合苦黄注射液对寒湿困脾型胆汁淤积性肝病患者的临床疗效[J]. 中成药, 2022, 44(5): 1475-1479.
[47] 刘海霞. 四逆散及其代表性成分芍药苷改善非酒精性脂肪肝的机制研究[D]: [博士学位论文]. 北京: 北京中医药大学, 2021.
[48] 冯贺龙, 王晓雪, 张福利. 基于网络药理学的四逆散保肝作用机制研究[J]. 中草药, 2020, 51(24): 6258-6268.
[49] 邓楠. 四逆散通过NLRP3/IL-1β通路治疗非酒精性脂肪肝的作用机制[D]: [硕士学位论文]. 北京: 北京中医药大学, 2020.
[50] 曹丹. 四逆散干预ANIT诱导大鼠胆汁淤积性肝病的作用机制研究[D]: [博士学位论文]. 北京: 北京中医药大学, 2023.
[51] 刁莹, 王仲娟, 李敏. 木犀草素对肝星状细胞活化和CCl4诱导小鼠肝纤维化的抑制作用及机制研究[J]. 河南师范大学学报(自然科学版), 2023, 51(5): 131-139.
[52] 王伟, 何平, 江小明. 木犀草素及其黄酮苷的抗炎、抗氧化作用[J]. 食品科学, 2020, 41(17): 208-215.
[53] Cummins, C.B., Wang, X., Nunez Lopez, O., Graham, G., Tie, H., Zhou, J., et al. (2018) Luteolin-mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway. International Journal of Molecular Sciences, 19, Article 1567. [Google Scholar] [CrossRef] [PubMed]